Ketamine for Combined Depression and Alcohol Use Disorder

The goal of this clinical trial is to investigate the effects of ketamine, in combination with standard inpatient addiction therapy, for adults with depression and alcohol use disorder. After screening and enrollment, participants will undergo baseline assessments of depression, measures of alcohol use and craving, as well as neurocognitive function. Participants will then be randomized to either ketamine (intervention) or midazolam (control). All participants will be admitted for standard inpatient addiction therapy while receiving ketamine or midazolam. Measures on safety, depression and alcohol use disorder will be repeatedly assessed during and after treatment. Final follow-up assessment is scheduled 6 months after baseline assessment.

NCT Number	NCT06090422
Lead Sponsor	University Hospital of North Norway Collaborators: University of Exeter
Conditions	Depression, Alcohol Use Disorder
Enrollment	34 participants
Start Date	2025-01-20
Primary Completion	2027-07-01 (estimated)
Study Completion	2027-07-01 (estimated)
Updated on ClinicalTrials.gov	2026-06-23